Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if an angiotensin II receptor blocker, valsartan
160 mg/day is more effective to reduce the incidence of cardiovascular events as compared to
40 mg/day in patients with moderate renal dysfunction.